Presage Biosciences, a Seattle, WA-based cancer biotechnology company advancing the use of intratumoral microdosing for Phase 0 investigation of early development candidates, closed a $6M Series D financing.
The round was led by pharmaceutical companies Takeda and Celgene.
This $6M investment brings the total equity raised by Presage to $26M and comes at an important time for Presage as we aim to broaden the use of the CIVO™ platform in clinical intratumoral microdosing studies with a range of biopharma partners.
Led by new CEO Dr. Richard Klinghoffer, former Chief Scientific Officer, who will take over responsibilities from Nathan Caffo, Presage Biosciences is an oncology company advancing a new drug development approach to assess novel therapeutics and combinations directly in living tumors with its patented CIVO™ intratumoral microdosing platform. The CIVO device is intended to enable simultaneous assessment of responses to multiple drugs or drug combinations directly in a single tumor while still in a patient’s body.
The company also partners with oncology-focused pharmaceutical companies through strategic alliances to provide preclinical data to discover effective drug combinations.
Caffo will continue to advise the company on business and strategic matters as Senior Corporate Advisor.